Astragalus Root Effects on Breast Tissue
Astragalus root and its components have complex, concentration-dependent effects on breast tissue that include both proliferative and anti-proliferative actions, with specific concerns for individuals with hormone-sensitive breast disease.
Estrogenic Effects and Proliferation Risk
The primary concern with Astragalus root in breast tissue relates to its phytoestrogenic components, particularly at low concentrations:
Calycosin, a major component of Astragalus root, stimulates proliferation of estrogen receptor (ER)-positive breast cancer cells (MCF-7) at low concentrations (2-8 µmol/L) through downregulation of the pro-apoptotic Bax gene and upregulation of the anti-apoptotic Bcl-2 gene 1.
Formononetin, another O-methylated isoflavone from Astragalus membranaceus root, promotes ER-positive cell proliferation at low concentrations (2-6 µM) through activation of a microRNA-375 and ERα feedback loop, with upregulation of p-Akt and Bcl-2 expression 2.
In vivo studies demonstrate that Astragalus root significantly increases blood estradiol levels and uterine weight in ovariectomized mice, confirming estrogenic activity in reproductive tissues 3.
Concentration-Dependent Biphasic Response
The tissue effects follow a biphasic pattern based on concentration:
At Low Concentrations (Proliferative):
- Calycosin at 2-8 µmol/L stimulates MCF-7 cell proliferation and decreases early apoptosis 1.
- Formononetin at 2-6 µM promotes ER-positive cell growth through ERα activation 2.
At Higher Concentrations (Anti-proliferative):
- Calycosin at 16-32 µmol/L inhibits cell proliferation 1.
- Astragalus mongholicus injection at 2×10⁻¹ to 2×10⁻⁴ g/mL inhibits MCF-7 cell proliferation, induces apoptosis (up to 16.7%), and arrests cells at G0-G1 or S phase even in the presence of physiological estradiol 4.
Anti-Tumor Mechanisms at Therapeutic Doses
When used at appropriate concentrations, Astragalus polysaccharides (APS) demonstrate anti-cancer properties:
APS downregulates CCNB1 and CDC6 expression while upregulating the tumor suppressor gene P53 in both MCF-7 and MDA-MB-231 cells in a dose-dependent manner 5.
APS attenuates breast cancer progression by regulating METTL3-mediated MAL2 m6A modification, reducing cell proliferation, migration, and invasion 6.
APS enhances cisplatin efficacy in triple-negative breast cancer by downregulating anti-apoptotic genes (Bcl2, Bcl-xL), upregulating pro-apoptotic genes (Puma, Cle-Caspase3), and suppressing epithelial-mesenchymal transition 7.
Suppression of Estrogen-Dependent Proliferation
Paradoxically, Astragalus root exhibits PPARα agonistic activity that may counteract estrogen-dependent proliferation:
Astragalus root upregulates PPARα mRNA expression in uterine tissue by 2.5-fold and ovarian tissue by 1.5-fold 3.
Despite increasing blood estradiol levels, Astragalus root significantly decreases uterine weight and mitochondrial 2,4-dienoyl-CoA reductase (mDECR) expression, suggesting suppression of estrogen-dependent endometrial hyperplasia 3.
Clinical Implications and Cautions
Critical Caveat for Hormone-Sensitive Breast Disease:
While ASCO guidelines do not specifically address Astragalus root, they emphasize caution with herbal supplements that may have estrogenic properties in patients with estrogen receptor-positive breast cancer 8. The concern parallels that of ginseng preparations, where ethanol extracts may possess estrogenic properties requiring caution in ER-positive breast cancer patients 8.
Key Considerations:
- The estrogenic effects of Astragalus components (calycosin, formononetin) at low concentrations pose theoretical risks for individuals with hormone-sensitive breast disease 1, 2.
- Over-the-counter dietary supplements vary significantly in content and quality; patients with cancer should not use dietary supplements without guidance from a health care professional 8.
- The specific estrogen receptor affinity (ERα vs. ERβ) of Astragalus components has not been thoroughly investigated, which is critical since ERβ binding may lead to decreased proliferation while ERα binding stimulates cell growth 8.
Practical Algorithm:
- Avoid Astragalus root supplements in patients with ER-positive breast cancer or hormone-sensitive breast disease due to proliferative effects of low-concentration phytoestrogens 1, 2.
- If considering use in non-hormone-sensitive breast cancer, ensure pharmaceutical-grade preparations at documented therapeutic concentrations that demonstrate anti-proliferative effects 5, 6, 7.
- Always consult with an oncology team before initiating any herbal supplement during or after breast cancer treatment 8.